Introduction {#Sec1}
============

Bisphosphonates (BPs) are antiresorptive drugs typically used to inhibit bone resorption. The latest reports show that BPs play an important role not only in achieving better bone mineral density but also in improving bone microarchitecture \[[@CR1], [@CR2]\].

The mechanism of action of the BPs is complex and multifactorial \[[@CR3]--[@CR5]\]. However BPs have an affinity for bone mineral and they act specifically on bone. During resorption of bone by osteoclasts, the ingestion of BPs interferes with specific intracellular processes, which impair osteoclast function and ultimately cause apoptosis or cell death. BPs also regulate osteoblastic functions such as proliferation and differentiation, prevent osteoblast apoptosis, modulate osteoblastic production of extracellular matrix proteins, and regulate osteoblastic expression and secretion of various growth factors and cytokines \[[@CR6], [@CR7]\]. Several recent studies, both preclinical and clinical, have focused on the potential application of the BPs to the problems of bone catabolism encountered in orthopaedics \[[@CR8]\]. BP therapy is effective in reducing bone turnover by decreasing bone resorption rather than bone formation. BPs are widely used in the treatment of many skeletal disorders such as osteoporosis, malignant hypercalcaemia, bone metastasis or Paget's disease \[[@CR9]--[@CR11]\]. Some studies have shown that nanomolar concentration of BPs had a positive effect on osteoblast and osteocytes \[[@CR12], [@CR13]\]. It is reasonable to believe that all those factors increase the bone density and may have a positive influence on bone implant osteointegration \[[@CR14], [@CR15]\]. It has also been shown that local use of BPs inhibits mineralisation of bone tissue and new bone formation \[[@CR16]\].

The microarchitectural structure of bone due to osteoclast-mediated resorption is of great clinical importance for many bone diseases. BP effects have been proven therapeutic in prevention of bone collapse and also in enhancement of implant fixation. Nevertheless, further large scale in vivo clinical trials are required to confirm all benefits concerning orthopaedic treatment.

We tried to determine whether there are any changes in the microarchitectural bone structure after local use of BP (Pamifos 60). The aim of the study was to see if BP-enriched cement used in rat models had a positive effect on bone formation.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

Wistar rats CRL(WI)WU BR were obtained from Mossakowski Medical Research Centre Polish Academy of Sciences. The experimental procedures were reviewed and approved by the Bioethical Committee of Animal Experimentation of the Medical University of Lublin.

Reagents {#Sec4}
--------

Bisphosphonate--pamidronate (Pamifos 60) was purchased from Vipharm (Warsaw, Poland). Bone cement was purchased from CMW 1, DePuy International Ltd, England.

Research was performed on 40 adult male Wistar rats, with mean weight 240 g. Rats were divided into four groups, ten rats each, in two control groups and two experimental groups. Rats in experimental groups were implanted with BP-enriched cement into the bone. While in the control groups, rats were implanted with clean bone cement (without BP). Because experimental groups were operated upon at different times, each group was associated with its own dedicated control group.

Animal model {#Sec5}
------------

The animals were anaesthetised using thiopental with depth of anaesthesia being assessed by pedal reflex. After each animal was anaesthetised, it was placed in a supine position and the skin over both tibia bones was shaved and disinfected. A skin incision was made over the proximal part of the tibia. After exposing the proximal tibias identical doses of freshly mixed bone cement were pressurised into the bone canals through a pre-drilled hole using syringes with modified 2.1-mm needles. Twenty rats were given pure cement (control groups), while the remaining 20 rats were given cement mixed with BPs. The wound was closed using Vicryl sutures and staples. Three weeks after surgery, rats from the first control group and from the first experimental group were anaesthetised using thiopental (30 mg/kg), and proximal parts of tibial bones were taken for examination by micro-computed tomography. We performed the same procedure six weeks after surgery for the remaining rats in the second control and second experimental groups.

Micro-computed tomography {#Sec6}
-------------------------

In micro-computed tomography the microCT SkyScan 1072 system was used. The SkyScan 1072 represented high-resolution desktop X-ray microtomography (Micro-CT) systems for in vitro scanning. Tomographic techniques were applied for the investigation of trabecular microarchitecture of the proximal physis of the tibial bone in all animals three and six weeks after surgery. Probes were located centrally on the tripod in the middle of the microtomography camera's area of sight. Then probes were scanned (magnification 34×; pixel 8.42; rotation step 0.23; exposure 1.9 s; gain 1). Raw scans were reconstructed with the nRecon program (Skyscan, Belgium). Then the CTan program (Skyscan, Belgium) was used for detailed analysis.

Bone samples were selected from identical levels, beneath the lowest level of applied cement or BP-enriched cement implanted into the bone chosen during micro-CT before 3D reconstruction, as the threshold. The thresholding procedure allowed us to distinguish clearly between the cement or BP-enriched cement and the bone tissue (Fig. [1](#Fig1){ref-type="fig"}). The comparison of morphometric parameters extracted from the different images revealed specific changes in bone morphology. Morphometric analyses were based on 3D algorithms of identical ROI (regions of interest; Fig. [2](#Fig2){ref-type="fig"}) in all probes, whereby a cylinder was positioned in the centre of the proximal physis of the tibia bone. That cylinder was visually located at an identical distance from the most distal part of the implanted cement which was used as a benchmark. We used standardised nomenclature and symbols for bone histomorphometry \[[@CR17]\]. In all microCT images variables such as bone volume (BV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) and trabecular number (Tb.N) were analysed.Fig. 1Micro-CT picture of tibial bone in rat six weeks after surgery with implanted cement which displayed the thresholding procedure before appropriate 3D reconstructionFig. 2Morphometric micro-CT analyses based on 3D algorithms of identical ROI (regions of interest)

Statistical analysis {#Sec7}
--------------------

All data are presented as means ± SD. Differences and correlations were considered significant when *p* \< 0.05. An ANOVA (analysis of variance) table was used for variance analysis to detect the existence of differences between the groups of rats that were investigated. All statistical calculations were performed using 6.0 STATISTICA software (StatSoft, Poland).

Results {#Sec8}
=======

The major finding of this study is that using BP-enriched cement results in distinct changes in bone microarchitecture (Fig. [3](#Fig3){ref-type="fig"}). High resolution micro-CT in vitro bone analysis showed an increase of bone volume (BV) in a group of rats implanted with BP-enriched cement after three weeks of treatment when compared to the control group. However there were no statistically significant differences between the groups studied (*P* = 0,444; Fig. [4](#Fig4){ref-type="fig"}). Nevertheless after six weeks of treatment statistics showed a significant increase of bone volume in rats implanted with BP-enriched cement (BV, *P* = 0.034; Fig. [5](#Fig5){ref-type="fig"}) compared to the group implanted with pure cement.Fig. 3Micro-CT cross-section picture of tibial bone in rat six weeks after surgery in the group of animals implanted with BP-enriched cement (*1*) compared to corresponding micro-CT picture of rat implanted with cement without BP (*2*)Fig. 4Bone volume (BV) in the group of rats implanted with BP-enriched cement three weeks after surgery compared to group of rats implanted with pure cementFig. 5Increase of bone volume (BV) in the group of rats implanted with BP-enriched cement six weeks after surgery compared to group of rats implanted with pure cement

We also noted a statistically significant increase of trabecular thickness (Tb.Th) in both groups (three and six weeks) of rats implanted with BP-enriched cement compared to rats implanted with pure cement (Tb.Th, *P* = 0.003; Tb.Th, *P* = 0.014; Figs. [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}). Though, three weeks after surgery we did not notice a significant decrease of trabecular separation in rats implanted with BP-enriched cement compared to rats implanted with cement without BP (Tb.Sp, *P* = 0.835; Fig. [8](#Fig8){ref-type="fig"}). Nonetheless six weeks after surgery we registered a significant decrease of that variable (Tb.Sp) between the control group and the group implanted with BP-enriched cement (*P* = 0.015; Fig. [9](#Fig9){ref-type="fig"}).Fig. 6Increase of trabecular thickness (Tb.Th) in the group of rats implanted with BP-enriched cement three weeks after surgery compared to the group of rats implanted with pure cementFig. 7Increase of trabecular thickness (Tb.Th) in the group of rats implanted with BP-enriched cement six weeks after surgery compared to the group of rats implanted with pure cementFig. 8Trabecular separation (Tb.Sp) in the group of rats implanted with BP-enriched cement six weeks after surgery compared to the group of rats implanted with pure cementFig. 9Decrease of trabecular separation (Tb.Sp) in the group of rats implanted with BP-enriched cement six weeks after surgery compared to groups of rats implanted with pure cement

In micro-CT analysis performed three and six weeks after surgery in groups of rats implanted with BP-enriched cement we did not obtain a statistically significant increase of trabecular numbers (*P* = 0.706; *P* = 0.231; Fig. [10](#Fig10){ref-type="fig"}).Fig. 10Trabecular numbers (Tb.N) in both groups implanted with BP-enriched cement three and six weeks after surgery compared to groups of rats implanted with pure cement

Discussion {#Sec9}
----------

The future potential use of BPs in orthopaedics encourages us to investigate the local use of this substance. Animal studies have shown that BPs inhibit bone resorption at the bone--implant interface \[[@CR18]\]. BPs can also inhibit osteolysis by interacting directly with the osteoclasts. Experimental results made by Agholme et al. showed that soaking bone grafts in BP solution can prevent their resorption and increase the local bone density in rats. They indicated that local use of BPs might be a great factor against bone resorption; improving the bone's microarchitecture and enhancing implant fixation without affecting the whole organism \[[@CR15]\]. Experimental in vitro and in vivo research has shown great potential of using BPs in healing fractured bones, reducing osteoarthritis or enhancing bone allografts ingrowth \[[@CR19]--[@CR24]\].

Our micro-CT results showed only beneficial effects on the bone's microarchitecture, which is similar to the observations of others \[[@CR25]\]. In the rat model presented we did not notice any aggravation in the bone's microarchitecture or other negative effects reported by other authors \[[@CR26], [@CR27]\].

High-resolution micro-computed tomography (microCT) imaging allowed us to assess bone morphology. Analyses based on 3D algorithms showed specific changes in three out of four variables that should be used to describe trabecular bone morphometry. Pamidronate implanted in cement did not affect the trabecular numbers, which is similar to other reports \[[@CR27], [@CR28]\]. Despite that fact some authors noticed significant changes in trabecular numbers during oral use of BPs in the paediatric population. Although they did not notice any changes in trabecular thickness, it was also noted that it might have been difficult to interpret because of the pathological process of specific diseases and the growth process in the young population \[[@CR29]\]. We proved that local use of pamidronate (Pamifos 60) in orthopaedic cement significantly increases two variables: bone volume and trabecular thickness. We also noticed a significant decrease of trabecular separation. When reporting micro CT results Gao et al. presented similar results. Although, their implants before surgery had been rinsed in a solution containing various BPs: pamidronate, zoledronic acid or ibandronate \[[@CR28]\]. Besides consistent changes in the parameters of trabecular microstructure they also reported effective induction of a greater restoration in the bone volume, which is similar to our findings.

Patients who need arthroplastic surgery are in high risk for osteopenia or osteoporosis \[[@CR30]\]. Several recent studies have shown the utility of local application of various BPs on titanium implants \[[@CR31]--[@CR35]\]. In our opinion local BP treatment may be more beneficial considering some of the side effects connected with oral BP treatment \[[@CR36], [@CR37]\]. Furthermore, our micro-CT analysis showed great potential in the local use of BP-enriched cement. In the data presented, implanted BP-enriched cement simply changes the bone turnover in normal rats' bone toward a positive balance between bone formation and bone resorption. As mentioned previously specific binding affinities and pharmacokinetics of pamidronate have different effects on osteoclasts and osteoblasts. However, its detailed mechanism of action is not completely understood. Pamidronate (Pamifos) appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. All those factors lead to positive effects on bone formation together with enhanced growth.

In our earlier report we proved that use of the bisphosphonate, Pamifos 60, that was present in the cement had a positive effect on bone turnover. BP stimulated increase in OPG and the RANKL decrease in the bone microenvironment markers in rat serum were important components of the mechanisms reducing bone resorption.

In this paper we also demonstrated the effectiveness of the idea of using BP-enriched cement in vitro in tibiae of rats. Our most significant findings based on micro-CT picture analysis allow us to start further work on more suitable applications of BP-enriched cement in humans. We believe that successful experiments will facilitate potential use of BP-enriched cement in clinical application.
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